ABCB1 and Cytochrome P450 Polymorphisms
- 1 August 2009
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Clinical Psychopharmacology
- Vol. 29 (4), 319-326
- https://doi.org/10.1097/jcp.0b013e3181acc372
Abstract
To examine the genetic factors influencing clozapine kinetics in vivo, 75 patients treated with clozapine were genotyped for CYPs and ABCB1 polymorphisms and phenotyped for CYP1A2 and CYP3A activity. CYP1A2 activity and dose-corrected trough steady-state plasma concentrations of clozapine correlated significantly (r = -0.61; P = 1 x 10), with no influence of the CYP1A2*1F genotype (P = 0.38). CYP2C19 poor metabolizers (*2/*2 genotype) had 2.3-fold higher (P = 0.036) clozapine concentrations than the extensive metabolizers (non-*2/*2). In patients comedicated with fluvoxamine, a strong CYP1A2 inhibitor, clozapine and norclozapine concentrations correlate with CYP3A activity (r = 0.44, P = 0.075; r = 0.63, P = 0.007, respectively). Carriers of the ABCB1 3435TT genotype had a 1.6-fold higher clozapine plasma concentrations than noncarriers (P = 0.046). In conclusion, this study has shown for the first time a significant in vivo role of CYP2C19 and the P-gp transporter in the pharmacokinetics of clozapine. CYP1A2 is the main CYP isoform involved in clozapine metabolism, with CYP2C19 contributing moderately, and CYP3A4 contributing only in patients with reduced CYP1A2 activity. In addition, ABCB1, but not CYP2B6, CYP2C9, CYP2D6, CYP3A5, nor CYP3A7 polymorphisms, influence clozapine pharmacokinetics.Keywords
This publication has 48 references indexed in Scilit:
- CYP3A7, CYP3A5, CYP3A4, and ABCB1 Genetic Polymorphisms, Cyclosporine Concentration, and Dose Requirement in Transplant RecipientsTherapeutic Drug Monitoring, 2008
- Evaluation of the role of P-glycoprotein in the uptake of paroxetine, clozapine, phenytoin and carbamazapine by bovine retinal endothelial cellsNeuropharmacology, 2005
- Increased Clozapine Plasma Concentrations and Side Effects Induced by Smoking Cessation in 2 CYP1A2 Genotyped PatientsTherapeutic Drug Monitoring, 2005
- Second-Generation (Atypical) Antipsychotics and Metabolic EffectsCNS Drugs, 2005
- Influence of Dose, Cigarette Smoking, Age, Sex, and Metabolic Activity on Plasma Clozapine ConcentrationsJournal of Clinical Psychopharmacology, 2004
- Omeprazole Reduces Clozapine Plasma ConcentrationsPharmacopsychiatry, 2003
- The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirementPharmacogenetics, 2003
- The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapineBritish Journal of Clinical Pharmacology, 1997
- Will Routine Therapeutic Drug Monitoring Have a Place in Clozapine Therapy?Clinical Pharmacokinetics, 1997
- Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in salivaPharmacogenetics, 1994